Earnings Release • Jan 20, 2023
Earnings Release
Open in ViewerOpens in native device viewer
Ad hoc announcement pursuant to Art. 53 LR
EQS-Ad-hoc: BB BIOTECH AG / Key word(s): Annual Results
BB Biotech AG closes the 2022 fiscal year with a loss
20-Jan-2023 / 07:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Ad hoc announcement pursuant to Art. 53 LR
January 20, 2023
BB Biotech AG closes the 2022 fiscal year with a loss
In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information about its results for its financial year 2022.
Based on its preliminary unaudited consolidated figures, BB Biotech AG reports a loss of approximately CHF 358 mn for the financial year 2022 (loss of CHF 405 mn in the previous year). For an investment company, the results reflect the share price development of the companies held in the portfolio.
The publication of all relevant portfolio data will take place on January 20, 2023 at 7:00 am and the complete annual report will be published on February 17, 2023.
For further information:
Media Relations
Bellevue Asset Management AG
Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Tanja Chicherio, [email protected]
www.bbbiotech.com
Company profile
BB Biotech AG is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss, German and Italian stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western Europe. BB Biotech is one of the world’s largest investors in this sector. The competent Board of Directors with its long-standing experience set the investment strategy and guidelines. Investment decisions are taken by the experienced investment management team of Bellevue Asset Management AG based on their extensive investment research.
20-Jan-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
| Language: | English |
| Company: | BB BIOTECH AG |
| Schwertstrasse 6 | |
| 8200 Schaffhausen | |
| Switzerland | |
| Phone: | +41 52 624 08 45 |
| E-mail: | [email protected] |
| Internet: | www.bbbiotech.ch |
| ISIN: | CH0038389992 |
| WKN: | A0NFN3 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Mailand, SIX |
| EQS News ID: | 1539437 |
| End of Announcement | EQS News Service |
1539437 20-Jan-2023 CET/CEST
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.